Skip to content

Evaluation of a podcast-based patient education program on health-related quality of life in psoriasis: a randomized controlled trial (PodPso)

Evaluation of a podcast-based patient education program on health-related quality of life in psoriasis: a randomized controlled trial (PodPso) - PodPso

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00038504
Enrollment
88
Registered
2025-11-20
Start date
2026-01-19
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

L40

Interventions

Group 1: Podcast-based training intervention (8 episodes with a total listening time of just under 5 hours and a content-supporting booklet over 4 weeks) Group 2: Passive control group (no interventio

Sponsors

Universitätsklinikum Schleswig-Holstein
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: o Underlying condition: medically confirmed diagnosis of psoriasis (regardless of severity and gender) o German language skills: native speaker or C1 level o Willingness to participate in a four-week intervention o Internet access o Ability to give informed consent

Exclusion criteria

Exclusion criteria: Pregnancy, severe mental illness (e.g., depression with suicidal thoughts, psychosis, eating disorder), substance-related addiction, cognitive disorders, other chronic skin conditions such as neurodermatitis, allergic skin reactions, hives, adults incapable of giving consent, participation in other studies or digital health applications, listening to less than 50% of the podcast episodes, serious unexpected events (e.g., complications of psoriasis requiring hospitalization or other acute health risks).

Design outcomes

Primary

MeasureTime frame
Mean change in the Dermatology Life Quality Index (DLQI) from baseline (week 0) to week 4 (end of the four-week podcast program) compared to the control group (“standard care”).

Secondary

MeasureTime frame
Therapy adherence, self-efficacy, disease knowledge, depression symptoms, anxiety symptoms, disease severity (PASI), usage rate, and satisfaction with the training format.

Countries

Germany

Contacts

Public ContactChristian Sina

Universitätsklinikum Schleswig-Holstein

christian.sina@uksh.de+49 451 3101 8400

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026